Condition: Histologically Confirmed Metastatic or Locally Advanced Breast Cancer With no Radical Topical Treatment Available · If There is Liver Metastasis, Which the Researcher Believes Will be Difficult to Evaluate the Response Accurately With Bone Metastasis or CT · Sponsor: Samsung Medical Center
This study is a prospective cohort study comparing metabolic response evaluation by F-18 FDG PET-CT versus conventional imaging for outcome stratification in patients with advanced breast cancer receiving first-line systemic therapy.
This description comes directly from the study's public registry record.
Yeon Hee Park, phD · +82-2-3410-1780 · yeonh.park@samsung.com
jungmin Lee, CRC · +82-2-2148-7609 · jm9356.lee@sbri.co.kr
Always discuss trial participation with your own doctor first.
| Samsung medical Center | Seoul, Gannam-gu, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07173868